Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02750215 · ClinicalTrials.gov registry record · Phase 2
A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
A Phase 2 study of Malignant Non-small Cell Neoplasm of Lung Stage IV, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02750215 is a Phase 2 study of Malignant Non-small Cell Neoplasm of Lung Stage IV that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02750215, a Phase 2 study of Malignant Non-small Cell Neoplasm of Lung Stage IV, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying capmatinib as a treatment for advanced non-small cell lung cancer with MET exon 14 skipping, where the participant has already received prior therapy with a MET inhibitor.
Conditions Studied
Interventions
- DRUG Capmatinib (INC280)
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-05 |
| Est. Completion | 2021-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02750215
The ClinicalTrials.gov registry entry for NCT02750215 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Non-small Cell Neoplasm of Lung Stage IV appearing as the primary indexed condition, and to 1 intervention - of which Capmatinib (INC280) is the first listed.
NCT02750215 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02750215 about?
NCT02750215 is a clinical study titled "A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor". This research study is studying capmatinib as a treatment for advanced non-small cell lung cancer with MET exon 14 skipping, where the participant has already received prior therapy with a MET inhibitor.
What is the current status of trial NCT02750215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-05. Estimated completion is 2021-05.
What conditions does trial NCT02750215 study?
This clinical trial studies the following conditions: Malignant Non-small Cell Neoplasm of Lung Stage IV.
What interventions are being tested in trial NCT02750215?
The interventions under investigation include: Capmatinib (INC280) (DRUG).
Who is sponsoring clinical trial NCT02750215?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02750215 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.